NSCLC
Pfizer lung cancer drug gets ‘rolling’ fast-track status in US
January 13, 2011Sales and Marketing Cancer, NSCLC, axitinib, bosutinib, crizotinib, non-small cell lung cancer
Pfizer has initiated a ‘rolling’ submission for its new oral ALK lung cancer drug crizotinib that could see it on …
Roche to develop diagnostic tools for Tarceva
November 23, 2010Sales and Marketing Genzyme, NSCLC, Roche, Tarceva, diagnostic
Roche has obtained a worldwide sub-license from Genzyme to develop a diagnostic kit for the detection of specific mutations for …
Novartis drops late stage lung cancer candidate
November 11, 2010Research and Development ASA404, Antisoma, NSCLC, Novartis, cancer research, lung cancer, non small cell lung cancer, non-small cell lung cancer
Novartis has discontinued phase III trials for its lung cancer candidate ASA404 after it once again failed to meet its …
Pfizer to seek US approval for crizotinib next year
November 1, 2010Research and Development, Sales and Marketing FDA submission, NSCLC, Pfizer, crizotinib, lung cancer, non-small cell lung cancer
Pfizer will submit its lung cancer candidate crizotinib to the FDA for US approval in the first half of next …
Lung cancer vaccine poised to begin phase IIb/III trials
September 1, 2010Research and Development NSCLC, TG4010, Transgene, cancer vaccine
French biotech firm Transgene has received positive scientific advice from the EMA for late stage trials of its new lung …
Sutent disappoints in lung cancer
August 24, 2010Research and Development, Sales and Marketing NSCLC, Pfizer, Sutent, Tarceva
Pfizer’s Sutent has failed to improve overall survival in lung cancer patients when combined with Roche’s Tarceva. Pfizer’s SUN 1087 …
Avastin will remain gold standard for lung cancer to 2018
June 20, 2010Decision Resources, NSCLC, Roche drug tipped to remain key to treatment, avastin
Industry analysts Decision Resources believes that Roche’s Avastin plus chemotherapy agents will remain as the gold standard for the treatment …
NICE rejects Tarceva maintenance treatment
June 17, 2010Sales and Marketing NICE, NSCLC, Roche, Tarceva, lung cancer
Roche’s Tarceva should not be used in lung cancer patients who have already been treated and whose disease remains stable, …
Nexavar fails in lung cancer trial
June 15, 2010Research and Development Bayer, NSCLC, Nexavar, Onyx
Bayer and Onyx Pharmaceutical’s oncology drug Nexavar has failed to meet its primary endpoint in a phase III study for …
Merck gains rights to cancer treatment
May 10, 2010Research and Development Ariad Pharmaceuticals, Merck & Co, NSCLC
Merck has acquired an exclusive license for a new cancer drug that’s in trials for a number of different forms …
Antisoma cancer drug fails in phase III
March 29, 2010Research and Development Antisoma, NSCLC, lung cancer
UK biotech Antisoma has suffered a disappointing late-stage failure with a potential lung cancer treatment it was developing with Novartis. …
Alimta recommended as maintenance therapy
March 1, 2010Sales and Marketing Alimta, Cancer, NSCLC, lilly
NICE has recommended Alimta as a maintenance treatment for people with locally advanced or metastatic non-small cell lung cancer. Patients …
Latest news from Datamonitor
June 22, 2007Research and Development, Sales and Marketing NSCLC, Novartis, Pfizer
Novartis receives FDA approval for blood pressure medicineNovartis has been granted final FDA approval for Exforge, its high blood pressure …
Latest content
Five Facts about cardiovascular disease
